Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer (Adv. Sci. 14/2025)
New Subtype of Small Cell Lung Cancer In article number 2413445, Dingzhi Huang, Mengjie Li, and co‐workers report that a HDAC7‐high small cell lung cancer (SCLC) subtype has a poor prognosis and have identified XPO1 as a druggable target in this subtype. Elevated HDAC7 predicts increased sensitivity to selinexor both in vitro and in organoids, suggesting selinexor as a promising therapeutic option for HDAC7‐high SCLC patients. [Image: see text]
Authors
- Dingzhi Huang (ORCID: https://orcid.org/0000-0002-2798-9459)
- Tingting Qin (ORCID: https://orcid.org/0000-0003-3810-7578)
- Hai‐Lin Liu
- Huiyan Liu (ORCID: https://orcid.org/0000-0002-2262-0775)
- Yantao Jiang
- Qingwu Du
- Ting Wang (ORCID: https://orcid.org/0000-0001-9248-4361)
- Wenting Liu (ORCID: https://orcid.org/0000-0002-8427-3414)
- Jingya Wang (ORCID: https://orcid.org/0000-0002-2527-6121)
- Mengjie Li (ORCID: https://orcid.org/0000-0002-0619-8754)
- Jian Wang (ORCID: https://orcid.org/0000-0001-7620-6740)
- Qi Xu (ORCID: https://orcid.org/0009-0008-2434-8403)
- Xueyang Li (ORCID: https://orcid.org/0000-0001-8161-4781)
- Junjie Yu (ORCID: https://orcid.org/0000-0002-0948-430X)
- Liuchun Wang
Publication Details
- Journal
- Advanced Science
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/advs.202570096
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00